8-K: Quanterix to Acquire Akoya Biosciences, Creating Integrated Biomarker Detection Platform

Quanterix announced its plan to acquire Akoya Biosciences in a stock-for-stock transaction, aiming to create the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.

Summary

• Quanterix has announced its plan to acquire Akoya Biosciences in a stock-for-stock transaction.
• Akoya shareholders will receive 0.318 shares of Quanterix stock for each Akoya share, resulting in pro forma ownership of 70% for Quanterix shareholders and 30% for Akoya shareholders.
• The acquisition aims to create a comprehensive suite of technologies for ultra-sensitive and spatial detection to improve diagnostic relevance and accuracy.
• The combined company will target high-growth markets in neurology, oncology, and immunology.
• The transaction is expected to close in the second quarter of 2025, pending shareholder and regulatory approvals.
• The combined company generated approximately $220 million in revenue for the trailing 12-month period ended September 30, 2024.
• The combined company expects to have approximately $175 million in cash at closing, after repaying Akoya's debt, transaction costs, and a $20 million payment for the EMISSION acquisition.
• The acquisition is projected to result in $40 million in cost synergies by the end of 2026, with $20 million expected within the first year after closing.
• Quanterix expects to maintain its financial flexibility to continue building a global diagnostic testing infrastructure for Alzheimer's disease, with a planned investment of $20 million by the end of the year.
• The combined company aims to achieve strong double-digit organic revenue growth and be cash flow positive in 2026.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the acquisition, highlighting the strategic benefits, potential synergies, and growth opportunities for the combined company. The management's comments are optimistic, and the overall tone suggests confidence in the success of the transaction.

Positives

• The acquisition creates a comprehensive platform for biomarker detection, integrating bloodand tissue-based analysis.
• The combined company will target high-growth markets in neurology, oncology, and immunology.
• The transaction is expected to improve the growth and scalability of both companies.
• Significant cost synergies of $40 million are anticipated by the end of 2026.
• The combined company will have a strong cash balance to reinvest in growth opportunities.
• The acquisition is expected to accelerate the path to profitability, with a target to be cash flow positive in 2026.
• The combined company will have a larger installed base of instruments, creating cross-selling opportunities.
• The acquisition supports Quanterix's strategy to expand into adjacencies and translate into Alzheimer's disease diagnostics.
• The combined company will have a broader range of technology offerings, improving its ability to serve customers.
• The acquisition is expected to enhance the company's ability to participate in the most dynamic subsectors of healthcare.

Negatives

• The transaction is subject to shareholder and regulatory approvals, which could delay or prevent the closing.
• Integration of the two companies could be challenging and may not result in the anticipated benefits and synergies.
• The acquisition may divert management's attention from ongoing business operations.
• Changes in Quanterix's share price before the closing of the transaction could affect the value of the deal.
• The issuance of Quanterix common stock in the transaction could have a dilutive effect.
• Potential adverse reactions or changes to business or employee relationships could result from the announcement or completion of the transaction.
• The possibility that the merger may be more expensive to complete than anticipated.
• The risk that necessary regulatory approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction.
• The risk that the anticipated benefits and synergies of the proposed transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the right of one or both parties to terminate the merger agreement.
• The outcome of any legal proceedings that may be instituted against Quanterix or Akoya.
• Failure to obtain necessary regulatory and stockholder approvals or to satisfy other conditions to the proposed transaction on a timely basis or at all.
• The possibility that the anticipated benefits and synergies of the proposed transaction are not realized when expected or at all.
• The proposed transaction may be more expensive to complete than anticipated.
• Diversion of management's attention from ongoing business operations and opportunities.
• Potential adverse reactions or changes to business or employee relationships.
• Changes in Quanterix's share price before the closing of the proposed transaction.
• Risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the proposed transaction.
• Other factors that may affect future results of Quanterix, Akoya, and the combined company.

Future Outlook

The combined company aims to achieve strong double-digit organic revenue growth and be cash flow positive in 2026.

Management Comments

• The transaction is a strong fit with our strategy and will create a true leader in our space with a one-of-a-kind integrated platform across the detection of blood and tissue-based protein biomarkers.
• The combined Akoya and Quanterix will serve three high growth markets across neurology, oncology, and immunology.
• This acquisition will provide us with the opportunity to thoughtfully invest in our combined R&D and expand our commercial reach.
• We're bringing together two highly complementary companies that will not only enhance the scale and efficiency of our organization, but will make a meaningful difference to our customers who are on the front lines of treating patients.

Industry Context

This acquisition reflects a growing trend in the life sciences industry towards integrated solutions that combine different technologies to provide more comprehensive insights into disease biology and improve diagnostic accuracy. The combination of Quanterix's ultra-sensitive biomarker detection with Akoya's spatial biology capabilities positions the combined company to capitalize on the increasing demand for multi-omic approaches in research and clinical settings.

Comparison to Industry Standards

• Quanterix's Simoa platform competes with technologies from companies like Luminex and Meso Scale Discovery (MSD) in the ultra-sensitive biomarker detection space.
• Akoya Biosciences competes with companies like NanoString Technologies and 10x Genomics in the spatial biology market.
• The combined company will aim to offer a more integrated solution compared to competitors that focus on either blood-based or tissue-based analysis alone.
• The $40 million in projected cost synergies is a significant figure, suggesting a substantial overlap in operations and potential for efficiency gains.
• The target to be cash flow positive in 2026 is ambitious and will require successful integration and execution of the combined company's strategy.

Management Changes

Stakeholder Impact

• Shareholders of both Quanterix and Akoya will be impacted by the transaction, with Akoya shareholders receiving Quanterix stock.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the integration.
• Customers of both companies are expected to benefit from the expanded product offerings and integrated solutions.
• The transaction is expected to improve the growth and scalability of both companies, benefiting stakeholders in the long term.

Next Steps

• Quanterix and Akoya will file a registration statement on Form S-4 with the SEC.
• A joint proxy statement/prospectus will be mailed to Quanterix and Akoya stockholders.
• Shareholder and regulatory approvals will be sought.
• An integration team will be formed to plan the integration of the two companies.
• The transaction is expected to close in the second quarter of 2025.
• The combined company will focus on achieving strong double-digit organic revenue growth and being cash flow positive in 2026.

Key Dates